StockNews.com Begins Coverage on Eagle Pharmaceuticals (NASDAQ:EGRX)

StockNews.com started coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a research note published on Tuesday. The brokerage issued a hold rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Stock Performance

Eagle Pharmaceuticals stock opened at $1.19 on Tuesday. Eagle Pharmaceuticals has a twelve month low of $0.00 and a twelve month high of $6.81. The business has a fifty day moving average of $0.81 and a two-hundred day moving average of $1.70.

Institutional Trading of Eagle Pharmaceuticals

Several hedge funds have recently modified their holdings of the company. Creative Planning bought a new position in shares of Eagle Pharmaceuticals during the 3rd quarter worth approximately $59,000. Jane Street Group LLC purchased a new position in Eagle Pharmaceuticals in the third quarter worth $96,000. DGS Capital Management LLC increased its position in shares of Eagle Pharmaceuticals by 44.9% during the third quarter. DGS Capital Management LLC now owns 71,728 shares of the specialty pharmaceutical company’s stock worth $268,000 after purchasing an additional 22,239 shares in the last quarter. Jacobs Levy Equity Management Inc. purchased a new stake in shares of Eagle Pharmaceuticals during the 3rd quarter valued at $453,000. Finally, RBF Capital LLC boosted its position in shares of Eagle Pharmaceuticals by 11.7% in the 3rd quarter. RBF Capital LLC now owns 143,078 shares of the specialty pharmaceutical company’s stock worth $534,000 after purchasing an additional 14,991 shares in the last quarter. 85.36% of the stock is owned by hedge funds and other institutional investors.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma.